Cisplatin /m2

Phase 3Small molecule

Merck & Co.

Cisplatin /m2 is one of 226 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

225

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Pleural MesotheliomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Pleural MesotheliomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cisplatin /m2

Merck & Co.

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Lenvima

Eisai

Preclinical

6 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Vidaza

Bristol-Myers Squibb

Preclinical

1 9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

REGN2810

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Head and Neck Squamous Cell Carcinoma

NCT03765918

Q2 2027

Phase 1/2Active, not recruiting

Locally Advanced or Metastatic Solid Tumors

NCT04198766

Q4 2027

Phase 2Active, not recruiting

Ovarian Cancer

NCT05406674

Q1 2030

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT06239727

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer

Unknown status·KKorean Gynecologic Oncology Group·Phase 2·NCT01487226·69 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Active, not recruiting·IInhibrx Biosciences, Inc·Phase 1/2·NCT04198766·296 enrolled

Ovarian Cancer1 trial

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05406674·40 enrolled

Pleural Mesothelioma1 trial

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04177953·92 enrolled

Advanced NSCLC1 trial

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

Withdrawn·HHangzhou ACEA Pharmaceutical Research Co., Ltd.·Phase 3·NCT03058094

7 more indications

Nasopharyngeal Carcinoma1 trial

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting·SSun Yat-sen University·Phase 3·NCT06239727·593 enrolled

Urothelial Carcinoma1 trial

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04602078·82 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01840579·57 enrolled

Advanced Solid Tumors1 trial

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02862457·34 enrolled

Pembrolizumab1 trial

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03631784·216 enrolled

Locally Advanced Head and Neck Cancer1 trial

An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.

Completed·—·Phase 4·NCT03998696·60 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03765918·714 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Cisplatin /m2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin /m2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin /m2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Cisplatin /m2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q4 2027

Q1 2030

Trials by Indication[1]

Cervical Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Ovarian Cancer1 trial

Pleural Mesothelioma1 trial

Advanced NSCLC1 trial

Nasopharyngeal Carcinoma1 trial

Urothelial Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Solid Tumors1 trial

Pembrolizumab1 trial

Locally Advanced Head and Neck Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News